CSIMarket
 


Amgen Inc   (AMGN)
Other Ticker:  
 
 

AMGN's Free Cash Flow Growth by Quarter and Year

Amgen Inc 's Free Cash Flow results by quarter and year




AMGN Free Cash Flow (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December 538.00 2,649.00 2,808.00 2,153.00
III Quarter September 2,760.00 2,978.00 2,418.00 3,368.00
II Quarter June 4,109.00 1,930.00 1,931.00 2,842.00
I Quarter March 1,064.00 2,164.00 2,104.00 2,134.00
FY   8,471.00 9,721.00 9,261.00 10,497.00



AMGN Free Cash Flow fourth quarter 2023 Y/Y Growth Comment
Amgen Inc reported drop in Free Cash Flow in the fourth quarter 2023 by -79.69% to $ 538.00 millions, from the same quarter in 2022.
The fall in the fourth quarter 2023 Amgen Inc 's Free Cash Flow compares unfavorably to the Company's average Free Cash Flow increase of 10.99%.

Looking into fourth quarter 2023 results within Biotechnology & Pharmaceuticals industry 3 other companies have achieved higher Free Cash Flow growth. While Amgen Inc ' s Free Cash Flow meltdown of -79.69% ranks overall at the positon no. 965 in the fourth quarter 2023.




AMGN Free Cash Flow ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December -79.69 % -5.66 % 30.42 % -14.36 %
III Quarter September -7.32 % 23.16 % -28.21 % -0.27 %
II Quarter June 112.9 % -0.05 % -32.05 % 100.99 %
I Quarter March -50.83 % 2.85 % -1.41 % 15.66 %
FY   -12.86 % 4.97 % -11.77 % 14.72 %

Financial Statements
Amgen Inc 's fourth quarter 2023 Free Cash Flow $ 538.00 millions AMGN's Income Statement
Amgen Inc 's fourth quarter 2022 Free Cash Flow $ 2,649.00 millions Quarterly AMGN's Income Statement
New: More AMGN's historic Free Cash Flow Growth >>


AMGN Free Cash Flow (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December -80.51 % -11.05 % 16.13 % -36.07 %
III Quarter September -32.83 % 54.3 % 25.22 % 18.51 %
II Quarter June 286.18 % -10.81 % -8.22 % 33.18 %
I Quarter March -59.83 % -22.93 % -2.28 % -15.12 %
FY (Year on Year)   -12.86 % 4.97 % -11.77 % 14.72 %




Free Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #75
Overall #965

Free Cash Flow Y/Y Growth Statistics
High Average Low
145.53 % 10.99 % -18.83 %
(Dec. 31. 2005)   (Dec 31 2019)
Free Cash Flow fourth quarter 2023 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #4
Healthcare Sector #75
Overall #965
Free Cash Flow Y/Y Growth Statistics
High Average Low
145.53 % 10.99 % -18.83 %
(Dec. 31. 2005)   (Dec 31 2019)

Free Cash Flow by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Amgen Inc 's Q/Q Free Cash Flow Growth


Free Cash Flow Q/Q Growth Statistics
High Average Low
5931.25 % 93.03 % -100 %
(June 30. 2004)  


AMGN's IV. Quarter Q/Q Free Cash Flow Comment
In the IV. Quarter 2023 Amgen Inc reported fall in Free Cash Flow sequentially by -80.51% to $ 538.00 millions, from $ 2,760.00 millions achived a quarter before.

If you look into present shortcoming in the quarter, you should take into consideration, that commonly IV. Quarter performance occur weaker in contrast to the preciding period, Caroline De Smet, an industry researcher said.

Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Free Cash Flow quarter on quarter growth. While Amgen Inc 's Free Cash Flow growth quarter on quarter, overall rank is 1317.


Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #112
Overall #1317
Free Cash Flow Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #7
Healthcare Sector #112
Overall #1317
Free Cash Flow Q/Q Growth Statistics
High Average Low
5931.25 % 93.03 % -100 %
(June 30. 2004)  


AMGN's IV. Quarter Q/Q Free Cash Flow Comment
In the IV. Quarter 2023 Amgen Inc disclosed fall in Free Cash Flow from the third quarter by -80.51% to $ 538.00 millions, from $ 2,760.00 millions released in the previous quarter.

If you analyse present shortcoming at the IV. Quarter, you suppose to presume, that usually IV. Quarter 2023 results emerge sluggish then in the third quarter, Caroline De Smet, an industry researcher mentioned.

Within Biotechnology & Pharmaceuticals industry 6 other companies have achieved higher Free Cash Flow quarter on quarter growth. While Amgen Inc 's Free Cash Flow growth quarter on quarter, overall rank is 1317.


Amgen Inc 's 12 Months Free Cash Flow Growth Year on Year


Free Cash Flow TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Free Cash Flow 12 Months Ending $ 9,583.00 $ 11,785.00 $ 11,915.00 $ 9,711.00 $ 10,657.00
Y / Y Free Cash Flow Growth (TTM) -10.08 % 9.5 % 15.85 % -5.03 % 5.09 %
Year on Year Free Cash Flow Growth Overall Ranking # 878 # 1133 # 1100 # 810 # 1385
Seqeuential Free Cash Flow Change (TTM) -18.68 % -1.09 % 22.7 % -8.88 % -0.98 %
Seq. Free Cash Flow Growth (TTM) Overall Ranking # 1183 # 1342 # 1359 # 695 # 848




Cumulative Free Cash Flow growth Comment
For the 12 months ended Dec 31 2023 Amgen Inc reported a decline in Free Cash Flow by -10.08% year on year, to $9,583 millions, compare to the 9.5% growth at Sep 30 2023.

In the Healthcare sector 72 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Total ranking has impoved so far to 878, from total ranking in previous quarter at 1133.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
145.53 %
10.99 %
-18.83 %
 

Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 73
Overall # 878

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
145.53 %
10.99 %
-18.83 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 86
S&P 500 # 1183
Cumulative Free Cash Flow growth Comment
For the 12 months ended Dec 31 2023 Amgen Inc reported a decline in Free Cash Flow by -10.08% year on year, to $9,583 millions, compare to the 9.5% growth at Sep 30 2023.

In the Healthcare sector 72 other companies have achieved higher trailing twelve month Free Cash Flow growth. While Total ranking has impoved so far to 878, from total ranking in previous quarter at 1133.

Free Cash Flow TTM Q/Q Growth Statistics
High Average Low
145.53 %
10.99 %
-18.83 %
 


Free Cash Flow TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 73
Overall # 878

Free Cash Flow TTM Y/Y Growth Statistics
High Average Low
145.53 %
10.99 %
-18.83 %
 


Free Cash Flow TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 86
S&P 500 # 1183




Other Free Cash Flow Growth
Biotechnology & Pharmaceuticals Industry Free Cash Flow Growth Trends and Statistics
Healthcare Sector Free Cash Flow Growth Statistics
Free Cash Flow Growth Trends for overall market
AMGN's Free Cash Flow Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Free Cash Flow Growth
Lowest Ranking Free Cash Flow Growth
Free Cash Flow Growth for AMGN's Competitors
Free Cash Flow Growth for Amgen Inc 's Suppliers
Free Cash Flow Growth for AMGN's Customers

You may also want to know
AMGN's Annual Growth Rates AMGN's Profitability Ratios AMGN's Asset Turnover Ratio AMGN's Dividend Growth
AMGN's Roe AMGN's Valuation Ratios AMGN's Financial Strength Ratios AMGN's Dividend Payout Ratio
AMGN's Roa AMGN's Inventory Turnover Ratio AMGN's Growth Rates AMGN's Dividend Comparisons



Companies with similar Free Cash Flow decline for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Free Cash Flow for the quarter ending Dec 31 2023
Sanofi-2.55%$ -2.546 millions
Inmode Ltd -2.62%$ -2.617 millions
Charles River Laboratories International inc -5.88%$ -5.884 millions
Mettler toledo International Inc -7.29%$ -7.291 millions
Envista Holdings Corporation-7.52%$ -7.525 millions
Bio rad Laboratories Inc -10.37%$ -10.366 millions
Inspire Medical Systems inc -10.39%$ -10.390 millions
Insulet Corporation-10.85%$ -10.848 millions
Laboratory Corporation Of America Holdings-11.32%$ -11.322 millions
Hologic Inc-13.18%$ -13.181 millions
Neurocrine Biosciences Inc -13.64%$ -13.636 millions
Gilead Sciences Inc -15.50%$ -15.504 millions
Bausch Health Companies Inc -17.89%$ -17.895 millions
Koru Medical Systems Inc-17.93%$ -17.932 millions
Progyny Inc -26.90%$ -26.900 millions
Ufp Technologies Inc -29.00%$ -28.997 millions
Enhabit Inc -29.27%$ -29.268 millions
Integra Lifesciences Holdings Corp-31.15%$ -31.153 millions
Cryoport inc -32.07%$ -32.074 millions
Qiagen N v -35.76%$ -35.764 millions
Abbvie inc -36.01%$ -36.012 millions
Regeneron Pharmaceuticals Inc -36.64%$ -36.642 millions
Pfizer Inc-38.94%$ -38.942 millions
Axonics Inc -39.81%$ -39.805 millions
Warby Parker Inc -42.68%$ -42.678 millions
Catalent Inc -47.66%$ -47.664 millions
Intuitive Surgical Inc -47.86%$ -47.865 millions
Incyte Corporation-47.92%$ -47.921 millions
Jazz Pharmaceuticals Plc-51.07%$ -51.066 millions
Edwards Lifesciences Corporation-51.70%$ -51.697 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com